Growing community of inventors

Adliswil, Switzerland

Peter Lichtlen

Average Co-Inventor Count = 4.00

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 33

Peter LichtlenAlcide Barberis (9 patents)Peter LichtlenAdrian Auf Der Maur (9 patents)Peter LichtlenDavid M Urech (6 patents)Peter LichtlenStefan Ewert (5 patents)Peter LichtlenPeter Lichtlen (9 patents)Alcide BarberisAlcide Barberis (22 patents)Adrian Auf Der MaurAdrian Auf Der Maur (17 patents)David M UrechDavid M Urech (47 patents)Stefan EwertStefan Ewert (15 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Esbatech, an Alcon Biomedical Research Unit LLC (5 from 36 patents)

2. Delenex Therapeutics Ag (2 from 5 patents)

3. Cell Medica Switzerland Ag (1 from 5 patents)

4. Esbatech, an Alcon Boimedical Research Unit, LLC (1 from 1 patent)


9 patents:

1. 9683034 - Stable and soluble antibodies inhibiting TNFα

2. 9512411 - Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK

3. 9315572 - Stable and soluble antibodies inhibiting TNF alpha

4. 8945563 - Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK

5. 8936785 - scFv antibodies which pass epithelial and/or endothelial layers

6. 8691228 - Stable and soluble antibodies inhibiting TNFα

7. 8389693 - Stable and soluble antibodies inhibiting TNFα

8. 8067547 - Stable and soluble antibodies inhibiting TNFα

9. 7902340 - Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/10/2025
Loading…